Mathew Blackman
Stock Analyst at Stifel
(1.52)
# 1497
Out of 5,333 analysts
67
Total ratings
54.84%
Success rate
14.53%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INGN Inogen | Maintains: Hold | 10 7 | 6.24 | 12.18% | 12 | May 8, 2025 | |
TNDM Tandem Diabetes Care | Maintains: Buy | 60 31 | 22.96 | 35.02% | 6 | May 1, 2025 | |
PEN Penumbra | Maintains: Strong Buy | 301 318 | 297.29 | 6.97% | 2 | Apr 24, 2025 | |
CLPT ClearPoint Neuro | Maintains: Strong Buy | 19 25 | 14.12 | 77.05% | 3 | Apr 1, 2025 | |
BBNX Beta Bionics | Initiates Coverage On: Buy | 25 | 13.91 | 79.73% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Hold | 245 293 | 310.64 | -5.68% | 3 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 92 94 | 55.68 | 68.82% | 5 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 18 24 | 12.15 | 97.53% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 6 3 | 1.28 | 134.38% | 1 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 50 | n/a | n/a | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 90 100 | 84.68 | 18.09% | 11 | Aug 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 19 16 | 12.22 | 30.93% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 18 11 | 8.55 | 28.65% | 4 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 | n/a | n/a | 3 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 18 16 | n/a | n/a | 2 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 64 | n/a | n/a | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 30 | n/a | n/a | 2 | Aug 26, 2020 |